ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
22. Mai 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
09. September 2022 08:30 ET
|
ABVC BioPharma, Inc.
New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
ABVC BioPharma Provides Vitargus® Update
18. August 2022 08:30 ET
|
ABVC BioPharma, Inc.
Phase II Vitargus® Clinical Trial Receives Local Ethics Committee Approval in Thailand FREMONT, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
16. Juni 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...